Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients

NCT04246684 is registered in ClinicalTrials.gov with Prof. Dr. med. Claus Rödel as lead sponsor.

NCT NCT04246684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-course Radiotherapy Versus Chemoradiotherapy, Followed by Consolidation Chemotherapy, and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients
Lead sponsor
Prof. Dr. med. Claus Rödel
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 5, 2020
Completion date
September 15, 2028
Enrollment
702 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer stage iii